Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS)

Berger Montague PC announced an investigation into Hims & Hers’ board over alleged fiduciary breaches, including potential improper sharing of private user health data with advertisers. The probe also targets claims of deceptive billing and subscription cancellations being made unnecessarily difficult. While no financial figures are provided, the allegations around health data privacy and billing practices raise regulatory and legal risk for the company.

Analysis

This is less about legal liability in the abstract and more about the integrity premium embedded in HIMS’s consumer-distribution model. If the market starts to believe acquisition data or subscription mechanics are being abused, the next-order effect is not just headline damage; it is higher CAC, weaker conversion from paid media, and a lower lifetime-value multiple because the business’s economics depend on repeat trust, not one-time transactions.

The immediate loser is HIMS, but the broader read-through is to any digitally distributed healthcare platform that monetizes through performance marketing. If ad platforms, app stores, or payment partners get stricter on health-data usage, the marginal cost of growth rises and the fastest path to margin expansion gets interrupted. More traditional healthcare names with stronger compliance moats — CVS, UNH, and to a lesser extent TDOC — can benefit at the margin if consumer trust rotates away from “direct-to-consumer convenience” toward incumbents with more institutional guardrails.

Catalyst-wise, the near-term risk is a discovery-driven escalation: even without a regulator, a plaintiff investigation can pull forward disclosures, reserve builds, and management distraction within 1-2 quarters. The bigger risk is 6-18 months: if there is any FTC/state attorney general follow-on, valuation should compress further because the market will price in structural limits on targeted marketing and potentially higher churn. What would reverse the trend is clean disclosure in upcoming filings that shows no material data-sharing exposure, no abnormal refund/chargeback trend, and no change in subscriber retention.

Contrarian view: this may be a governance overhang rather than a franchise break. If the allegations are overstated and the company can demonstrate that advertiser data was anonymized or immaterial, the selloff could be an opportunity because the underlying consumer demand may be intact. But that setup is only attractive after the market sees hard evidence in 10-Q/10-K language, not before.

Key Decisions for Investors

• Short HIMS on any rally over the next 1-5 trading days; use a tight risk cap because the event is allegation-driven, not adjudicated. Falsify the short if management provides a clean disclosure update with no revenue, churn, or reserve impact in the next earnings cycle.
• Pair trade: short HIMS / long CVS or UNH for a 1-3 month horizon. The thesis is that compliance-heavy incumbents gain relative trust while HIMS absorbs a multiple haircut from governance uncertainty; stop the pair if HIMS re-rates back above the pre-news valuation band on stable retention metrics.
• If options liquidity is sufficient, buy HIMS put spreads 1-3 months out rather than outright puts; the catalyst path is uncertain and the spread limits premium decay if the matter stalls. Reduce if the stock closes above the post-news gap-fill level on above-average volume.
• Watch the next 10-Q/earnings call for any language on refunds, chargebacks, subscriber cancellations, or compliance reserves. If any of those trends worsen, add to the short; if all remain stable, the market may be overpricing the legal overhang.
• For a lower-conviction alternative, express the view via a basket: short HIMS against a healthcare services basket (CVS, UNH, TDOC) to isolate trust/compliance risk from broad market beta.